Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,182.89
+3.58 (+0.30%)
Streaming Delayed Price
Updated: 9:52 AM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
June 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Via
Benzinga
Stock Split Watch: 3 Growth Stocks That Could Be Next
June 07, 2024
Success has some downsides, including a much higher stock price.
Via
The Motley Fool
What's Going On With FibroGen Stock Tuesday?
June 04, 2024
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial...
Via
Benzinga
Exposures
Product Safety
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
June 04, 2024
Via
Benzinga
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
June 04, 2024
Via
Benzinga
2 Biotech Stocks to Buy in May
May 25, 2024
You could buy these in any month, really.
Via
The Motley Fool
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
May 20, 2024
Via
Benzinga
FibroGen Stock Is Surging After The Bell: What's Going On?
June 03, 2024
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial...
Via
Benzinga
Exposures
Product Safety
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
June 03, 2024
Via
Benzinga
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
May 31, 2024
The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from...
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
May 17, 2024
Via
Benzinga
What's Going On With Biohaven Stock Wednesday?
May 29, 2024
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates.
Via
Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24, 2024
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.
Via
Benzinga
Topics
Data Breach
Exposures
Information Security
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
May 23, 2024
It might not be too late to invest in these impressive growth stocks.
Via
The Motley Fool
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
May 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
May 19, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
May 17, 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
May 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
These 2 No-Brainer Growth Stocks Are Breaking New Ground
May 16, 2024
The future keeps getting brighter for these companies.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
May 14, 2024
Via
Benzinga
Week Of May 13, 2024: What's In Store For The Markets
May 13, 2024
Timeless Wisdom and timely ideas including general market commentary along with stocks to watch.
Via
Talk Markets
Healthcare And Biotech Investing 101: What You Need To Know.
May 13, 2024
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sell In May? No Way!
May 11, 2024
Many investors and members of the financial media have been asking if it would be prudent to heed the old Wall Street adage to “sell in May and go away.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.